Sign in Subscribe

Topic

m&a

A collection of 7 issues

Regeneron acquires 23andMe to access DNA profiling IP

Regeneron Inc has announced it has entered into an Asset Purchase Agreement to acquire 23andMe for US$ 256 Million. The planned purchase aims to strengthen Regeneron’s ongoing leadership in genetics-guided research and drug development to help people with serious diseases. Regeneron has stated that it plans to: * maintain the

M&A: Week 13

In this week's M&A review In this week's M&A review * Softbank to acquire Ampere Computing in US$ 6.5 billion deal * Google to acquire Wiz - the company's most expensive deal to date Softbank to acquire Ampere Computing in US$

Cortigent’s Patent Portfolio: Aging IP or Strategic Reset?

Vivani Medical has announced plans to spin off Cortigent as an independent publicly-traded company. The spin-off is planned to be completed by Q3 2025. Vivani Medical was formed in 2022 through the merger of Second Sight Medical and Nano Precision Medical. Cortigent, previously known as Second Sight Medical Products, has

M&A: Week 12

In this week's M&A review * 2Seventybio to be acquired by Bristol Myers Squibb for US$286 million in cash deal 2Seventybio to be acquired by Bristol Myers Squibb for US$286 million in cash deal 2Seventybio has announced a definitive merger agreement under which Bristol Myers

M&A: Week 11

In this week's M&A review * Jazz Pharmaceuticals acquires Chimerix for approximately US$935 million in cash Jazz Pharmaceuticals acquires Chimerix for approximately US$935 million in cash Through the acquisition Jazz Pharmaceuticals gains access to dordaviprone, a novel small molecule therapy in development for H3 K27M-mutant

M&A: Week 10

In this week's M&A review * Bluebird bio to be acquired by Carlyle and SK Capital Bluebird bio to be acquired by Carlyle and SK Capital According to report the company has been acquired for about US$30 million. Carlyle and SK Capital will provide primary capital

A US$ 250 million Play for Spinal Stimulation Patents

Globus Medical announced its US$ 250 million acquisition of Nevro on February 6, 2025, gaining control of their large spinal cord stimulation (SCS) patent portfolio. This acquisition expands Globus' neuromodulation patent portfolio and strengthens its position in the US$13.3 billion spinal device market. A market that is